Indefinite Delivery Contract SPE2DX17D9142

The federal Indefinite Delivery Contract (IDC) awarded to DMS Pharmaceutical Group Inc. by the Defense Logistics Agency (DLA) under the SPE2DB program is a single-award contract valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain and providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

The IDC was awarded to DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, that specializes in providing a range of pharmaceutical products and medical supplies to federal government agencies, particularly the Department of Defense (DoD). The company has demonstrated its capability to deliver a diverse array of pharmaceutical products to the DLA through previous contract awards, including delivery orders for specialized medications such as Xolair, Trikafta, Keytruda, Botox, Nucala, and various other prescription drugs and medical supplies.